Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Arrowhead pharmaceuticals, inc. save search
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
Published: 2023-11-13 (Crawled : 15:30) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -1.45%
H: 0.41%
C: -2.26%
phase 2
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
Published: 2023-05-23 (Crawled : 13:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.36%
H: 5.18%
C: -1.01%
study phase 2
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
Published: 2022-10-11 (Crawled : 12:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.16%
H: 4.72%
C: 2.32%
pharmaceuticals study phase 2
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Published: 2022-06-27 (Crawled : 11:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 1.09%
H: 1.36%
C: 0.93%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.55%
H: 1.01%
C: -2.68%
results phase 2
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
Published: 2022-04-26 (Crawled : 12:20) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
treatment phase 2 hypercholesterolemia
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Published: 2022-03-15 (Crawled : 12:30) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 1.89%
H: 2.65%
C: 0.87%
treatment clearance phase 1 phase 2
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
Published: 2022-02-24 (Crawled : 13:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -4.48%
H: 10.36%
C: 10.21%
phase 2 phase 2b enroll
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published: 2022-02-18 (Crawled : 13:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -0.09%
H: 2.1%
C: -1.97%
treatment als disease media phase 1 phase 2 phase 3
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
Published: 2021-11-15 (Crawled : 19:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -3.29%
H: 0.86%
C: -10.19%
phase 2 hepatitis phase 2b injection infections chronic hepatitis b
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -0.69%
H: 1.61%
C: 0.11%
disease media treatment phase 1 phase 2 clearance
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Published: 2021-09-30 (Crawled : 12:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 1.24%
H: 3.54%
C: 1.71%
treatment phase 2 phase 2b
Arrowhead Earns $10 Million Phase 1 Milestone Payment
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: -6.56%
phase 1 phase 2 phase 3 milestone
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
Published: 2021-07-02 (Crawled : 16:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -20.96%
H: 0.0%
C: 0.0%
phase 1 phase 2 phase 3
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
Published: 2021-06-30 (Crawled : 13:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -0.6%
H: 4.07%
C: 2.23%
treatment phase 2 phase 2b
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Published: 2021-06-03 (Crawled : 12:15) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.18%
H: 0.65%
C: 0.21%
treatment phase 2 phase 2b
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Published: 2021-03-01 (Crawled : 14:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 1.86%
H: 4.08%
C: 3.25%
phase 2 phase 2b
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Published: 2021-01-25 (Crawled : 13:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -0.27%
H: 3.45%
C: 2.79%
phase 2 treatment phase 2b
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.